Patent Yard Sign in
Canadian application, no grantCanada

Novel tyloindicines and related processes, pharmaceutical compositions and methods

CA 2474848 A1 · Owner: Baker, David C. · Inventors: Cheng, Yung-Chi; Baker, David C.; Zhong, Sanbao

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

The invention provides novel tyloindicines analogues and related processes pharmaceutical compositions, and methods. The novel tyloindicines are useful in a wide variety of antiviral, antineoplastic antibacterial, and anti-, inflammatory applications. Preferred embodiments of the instant invention include the novel tyloindicine designated herein as compound IT-3 (NSC- 716802). Compounds of the instant invention have exhibited potent antiviral and anticancer activity in vitro. The invention further provides novel methods of treating neoplastic, bacterial, viral and anti-inflammatory disorders , using tyloindicines including the novel tyloindicine analogues of the instant invention. The …

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed February 12, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 12, 2023.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 12, 2025.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledFebruary 12, 2003
GrantedNo grant recorded
Term endedFebruary 12, 2023
Patent numberCA 2474848 A1
Classification (IPC)C07D471/04 +2 more

Timeline

Timeline From CIPO dates

2004200620082010201220142016201820202022Application filedFeb 12, 2003Term endedFeb 12, 2023

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.